CDC Highlights Significant Increase in U.S. Rabies Exposures and Anti-Rabies Immunoglobulin Utilization; Kamada Confirms Sufficient KedRAB® Supply to Meet Increased Demand
REHOVOT, Israel, and HOBOKEN, N.J., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA) (the “Company”), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field, today confirmed that it maintains sufficient KedRAB ® supply and manufacturing capacity to meet increased demand for the product in the United States. The confirmation follows a Health Advisory published by the U.S. Centers for Disease Control and Prevention (CDC) on September 10, 2026, reporting a significant nationwide year-over-year increase in human rabies exposures and the use of rabies post-exposure prophylaxis (PEP). The CDC Health Advisory is available at: https://www.cdc.gov/han/php/notices/han00533.html .